Parkinson's disease: Oxidative stress and therapeutic approaches

Neurological Sciences

Volumn 31, Issue 5, 2010, Pages 531-540

  Surendran, Sankar ^a   Rajasankar, Srinivasagam ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Melmaruvathur Adhiparasakthi Institute of Medical Sciences   (India)

Author keywords

Antioxidant; Canavan disease; Neurodegeneration; Parkinson's disease; Withania somnifera

Indexed keywords

ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; AMANTADINE; CATALASE; DJ 1 PROTEIN; EPIGALLOCATECHIN GALLATE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; N ACETYLASPARTIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME; RASAGILINE; RESVERATROL; SALSOLINOL; SUPEROXIDE DISMUTASE; UBIDECARENONE; UBIQUITIN; WITHANIA SOMNIFERA EXTRACT;

ASTROCYTE; CANAVAN DISEASE; CLINICAL FEATURE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; ENZYME ACTIVITY; GENE MUTATION; HUMAN; LIPID PEROXIDATION; MOTOR PERFORMANCE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN DEGRADATION; REVIEW;

ANIMALS; ANTIOXIDANTS; ASPARTIC ACID; BRAIN; CATECHOLAMINES; HUMANS; LIPID PEROXIDATION; NITRIC OXIDE; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITINS;

EID: 78049348191     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-010-0245-1     Document Type: Review

References (107)

1. J Parkinson 2002 An essay on the shaking palsy. 1817 J Neuropsychiatry Clin Neurosci 14 223 236 11983801
2. P Anglade S Vyas F Javoy-Agid MT Herrero PP Michel, et al. 1997 Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease Histol Histopathol 12 25 31 9046040
3. ZI Alam A Jenner SE Daniel AJ Lees N Cairns, et al. 1997 Oxidative DNA damage in the parkinsonian brain; a selective increase in 8-hydroxyguanine in substantia nigra? J Neurochem 69 1196 1203 9282943
4. P Delaveau P Salgado-Pineda T Witjas J Micallef-Roll E Fakra JP Azulay O Blin 2009 Dopaminergic modulation of amygdala activity during emotion recognition in patients with Parkinson disease J Clin Psychopharmacol 29 548 554 19910719
5. S Rajasankar T Manivasagam S Surendran 2009 Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson's disease Neurosci Lett 454 11 15 19429045
6. W Kim H Erlandsen S Surendran RC Stevens A Gamez K Michols-Matalon SK Tyring R Matalon 2004 Trends in enzyme therapy for phenylketonuria Mol Ther 10 220 224 15294168
7. GU Höglinger G Carrard PP Michel F Medja A Lombès M Ruberg B Friguet EC Hirsch 2003 Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease J Neurochem 86 1297 1307 12911637
8. KS McNaught P Jenner 2001 Proteasomal function is impaired in substantia nigra in Parkinson's disease Neurosci Lett 297 191 194 11137760
9. A Zimprich S Biskup P Leitner P Lichtner, et al. 2004 Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology Neuron 44 601 607 15541309
10. M Orth AH Schapira 2002 Mitochondrial involvement in Parkinson's disease Neurochem Int 40 533 541 11850110
11. M Gerlach P Riederer 2003 Current preclinical findings on substances against Parkinson's disease Nervenarzt 74 S2 6 12624677
12. AH Rajput HH Sitte A Rajput ME Fenton C Pifl O Hornykiewicz 2008 Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation Neurology 70 1403 1410 18172064
13. S Rajasankar T Manivasagam V Sankar S Prakash R Muthusamy A Krishnamurti S Surendran 2009 Withania somnifera improves antioxidants, catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse J Ethnopharmacol 125 369 373 19666100
14. R Deumens A Blokland J Prickaerts 2002 Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway Exp Neurol 175 303 317 12061862
15. PM Keeney J Xie RA Capaldi JP Bennett Jr 2006 Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled J Neurosci 26 5256 5264 16687518
16. S Surendran 2009 Upregulation of N-acetylaspartic acid alters inflammation, transcription and contractile associated protein levels in the stomach and smooth muscle contractility Mol Biol Rep 36 201 206 17943458
17. DT Dexter FR Wells AJ Lees F Agid Y Agid P Jenner CD Marsden 1989 Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease J Neurochem 52 1830 1836 2723638
18. A Yoritaka N Hattori K Uchida M Tanaka ER Stadtman Y Mizuno 1996 Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease Proc Natl Acad Sci USA 93 2696 2701 8610103
19. J Zhang G Perry MA Smith D Robertson SJ Olson DG Graham TJ Montine 1999 Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons Am J Pathol 154 1423 1429 10329595
20. DG Graham SM Tiffany WR Bell Jr WF Gutknecht 1978 Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro Mol Pharmacol 14 644 653 567274
21. ZI Alam SE Daniel AJ Lees DC Marsden P Jenner B Halliwell 1997 A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease J Neurochem 69 1326 1329 9282961
22. E Floor MG Wetzel 1998 Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay J Neurochem 70 268 275 9422371
23. L Miao DK St Clair 2009 Regulation of superoxide dismutase genes: Implications in disease Free Radic Biol Med 47 344 356 19477268
24. Surendran S, Matalon R, Tyring SK (2007) Neurochemical changes and therapeutical targets in phenylketonuria (PKU). In: Surendran S (ed) Neurochemistry of metabolic diseases-lysosomal storage diseases, phenylketonuria and Canavan disease. Transworld Research Network, India, pp 105-118
25. E Gałecka R Jacewicz M Mrowicka A Florkowski P Gałecki 2008 Antioxidative enzymes-structure, properties, functions Pol Merkur Lekarski 25 266 268 19112846
26. HL Martin P Teismann 2009 Glutathione-a review on its role and significance in Parkinson's disease FASEB J 23 10 3263 3272 19542204
27. HS Maker C Weiss DJ Silides G Cohen 1981 Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates J Neurochem 36 589 593 7463078
28. DT Dexter CJ Carter FR Wells F Javoy-Agid Y Agid A Lees P Jenner CD Marsden 1989 Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease J Neurochem 52 381 389 2911023
29. E Sofic P Riederer H Heinsen H Beckmann GP Reynolds G Hebenstreit MB Youdim 1988 Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain J Neural Transm 74 199 205 3210014
30. PK Pearce A Owen S Daniel P Jenner CD Marsden 1997 Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease J Neural Transm 104 661 677 9444566
31. E Sofic KW Lange K Jellinger KP Riederer 1992 Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease Neurosci Lett 142 128 130 1454205
32. NN Cole D Dieuliis P Leo DC Mitchell RL Nussbaum 2008 Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification Exp Cell Res 314 2076 2089 18440504
33. S Shavali HM Brown-Borg M Ebadi J Porter 2008 Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells Neurosci Lett 439 125 128 18514418
34. JJ Palacino D Sagi MS Goldberg S Krauss C Motz M Wacker J Klose J Shen 2004 Mitochondrial dysfunction and oxidative damage in parkin-deficient mice J Biol Chem 279 18614 18622 14985362
35. M Muftuoglu B Elibol O Dalmizrak A Ercan G Kulaksiz H Ogüs T Dalkara N Ozer 2004 Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations Mov Disord 19 544 548 15133818
36. L Silvestri V Caputo E Bellacchio L Atorino B Dallapiccola EM Valente G Casari 2005 Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism Hum Mol Genet 14 3477 3492 16207731
37. HH Hoepken S Gispert B Morales O Wingerter D Del Turco A Mülsch RL Nussbaum K Müller S Dröse T Brandt U Deller B Wirth AP Kudin WS Kunz G Auburger 2007 Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6 Neurobiol Dis 25 401 411 17141510
38. L Zhang M Shimoji B Thomas DJ Moore SW Yu NI Marupudi R Torp IA Torgner OP Ottersen TM Dawson VL Dawson 2005 Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis Hum Mol Genet 14 2063 2073 15944198
39. RM Canet-Aviles MA Wilson DW Miller R Ahmad C McLendon S Bandyopadhyay MJ Baptista D Ringe GA Petsko MR Cookson 2004 The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization Proc Natl Acad Sci USA 101 9103 9108 15181200
40. AB West DJ Moore S Biskup A Bugayenko WW Smith CA Ross VL Dawson TM Dawson 2005 Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity Proc Natl Acad Sci USA 102 16842 16847 16269541
41. KM Strauss LM Martins H Plun-Favreau FP Marx S Kautzmann D Berg T Gasser Z Wszolek T Müller A Bornemann H Wolburg J Downward O Riess JB Schulz R Krüger 2005 Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease Hum Mol Genet 14 2099 2111 15961413
42. L Ravagnan T Roumier G Kroemer 2002 Mitochondria, the killer organelles and their weapons J Cell Physiol 192 131 137 12115719
43. AM Penn T Roberts J Hodder PS Allen G Zhu WR Martin 1995 Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle Neurology 45 2097 2099 7501166
44. H-M Baik BY Choe H-K Lee T-S Suh BC Son J-M Lee 2002 Metabolic alterations in Parkinson's disease after thalamotomy, as revealed by H MR spectroscopy Korean J Radiol 3 180 188 12271163
45. TA Griffin D Nandi M Cruz HJ Fehling LV Kaer JJ Monaco RA Colbert 1998 Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits J Exp Med 187 97 104 9419215
46. DJ Kingsbury TA Griffin RA Colbert 2000 Novel propeptide function in 20 S proteasome assembly influences beta subunit composition J Biol Chem 275 24156 24162 10816564
47. H Lindå H Hammarberg F Piehl M Khademi T Olsson 1999 Expression of MHC class I heavy chain and beta2-microglobulin in rat brainstem motoneurons and nigral dopaminergic neurons J Neuroimmunol 101 76 86 10580816
48. M Sawada K Imamura T Nagatsu 2006 Role of cytokines in inflammatory process in Parkinson's disease J Neural Transm Suppl 70 373 381 17017556
49. S Surendran 2001 Possible role of fas antigen (CD 95) in human amniotic epithelial cell death: an in vitro study Cell Biol Int 25 485 488 11401336 (Pubitemid 32530361)
50. Y Chu H Dodiya P Aebischer CW Olanow JH Kordower 2009 Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions Neurobiol Dis 35 385 398 19505575
51. E Masliah E Rockenstein I Veinbergs M Mallory M Hashimoto A Takeda Y Sagara A Sisk L Mucke 2000 Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders Science 287 1265 1269 10678833
52. M Hashimoto LJ Hsu Y Xia A Takeda A Sisk M Sundsmo E Masliah 1999 Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro Neuroreport 10 717 721 10208537
53. J Jungmann HA Reins C Schobert S Jentsch 1993 Resistance to cadmium mediated by ubiquitin-dependent proteolysis Nature 361 369 371 8381213
54. KS McNaught LM Björklund R Belizaire O Isacson P Jenner CW Olanow 2002 Proteasome inhibition causes nigral degeneration with inclusion bodies in rats Neuroreport 13 1437 1441 12167769
55. CN Larsen BA Krantz KD Wilkinson 1998 Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases Biochemistry 37 3358 3368 9521656
56. BI Giasson VM Lee 2001 Parkin and the molecular pathways of Parkinson's disease Neuron 31 885 888 11580890
57. E Leroy R Boyer G Auburger B Leube G Ulm E Mezey G Harta MJ Brownstein S Jonnalagada T Chernova A Dehejia C Lavedan T Gasser PJ Steinbach KD Wilkinson MH Polymeropoulos 1998 The ubiquitin pathway in Parkinson's disease Nature 395 451 452 9774100
58. Y Liu L Fallon HA Lashuel Z Liu PT Lansbury Jr 2002 The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility Cell 111 209 218 12408865
59. T Kitada S Asakawa N Hattori H Matsumine Y Yamamura S Minoshima M Yokochi Y Mizuno N Shimizu 1998 Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism Nature 392 605 608 9560156 (Pubitemid 28207717)
60. R von Coelln VL Dawson TM Dawson 2004 Parkin-associated Parkinson's disease Cell Tissue Res 318 175 184
61. M Naoi W Maruyama P Doster K Kohda T Kaiya 1996 A novel enzyme enantio-selectively synthesizes (R)salsolinol, a precursor of a dopaminergic neurotoxin, N-methyl(R)salsolinol Neurosci Lett 212 183 186 8843103
62. M Naoi W Maruyama Y Akao H Yi 2002 Dopamine-derived endogenous N-methyl-(R)-salsolinol: its role in Parkinson's disease Neurotoxicol Teratol 24 579 591 12200189
63. F Musshoff P Schmidt R Dettmeyer F Priemer H Wittig B Madea 1999 A systematic regional study of dopamine and dopamine-derived salsolinol and norsalsolinol levels in human brain areas Forensic Sci Int 105 1 11 10605071
64. F Musshoff P Schmidt R Dettmeyer F Primer K Jachau B Madea 2000 Determination of dopamine and dopamine-derived (R)-/(S)-salsolinol and norsalsolinol in various human brain areas using solid-phase extraction and gas chromatography/mass spectrometry Forensic Sci Int 113 359 366 10978649
65. BE Toth K Homicsko B Radnai W Maruyama JE Demaria M Vecsernyes MIK Fekete F Fulop M Naoi ME Freeman GM Nagy 2001 Salsolinol is a putative endogenous neuro-intermediate lobe prolactin-releasing factor J Neuroendocrinol 13 1042 1050 11722700
66. M Naoi W Maruyama GM Nagy 2004 Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains Neurotoxicol 25 193 204
67. A Storch A Kaftan K Burkhard J Schwartz 2000 1-Methyl-6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline (salsolinol) is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism Brain Res 855 67 75 10650131
68. W Maruyama T Abe H Tohgi P Dostert M Naoi 1996 A dopaminergic neurotoxin, (R)-N-methylsalsolinol increases in parkinsonian cerebrospinal fluid Ann Neurol 40 119 122 8687181
69. Surendran S, Kumaresan G (2007) Neurochemical changes and therapeutic approaches in Canavan disease. In: Surendran S (ed) Neurochemistry of metabolic diseases-lysosomal storage diseases, phenylketonuria and Canavan disease. Research Signpost, India, pp 119-132
70. S Surendran 2005 Canavan disease: genomic interaction and metabolic levels EXCLI J 4 77 86
71. S Surendran R Matalon SK Tyring 2006 Upregulation of aspartoacylase activity in the duodenum of obesity induced diabetes mouse: implications on diabetic neuropathy Biochem Biophys Res Commun 345 973 975 16707098
72. S Surendran FJ Bamforth A Chan SK Tyring SI Goodman R Matalon 2003 Mild elevation of N-acetylaspartic acid and macrocephaly: diagnostic problem J Child Neurol 18 809 812 14696913
73. S Surendran 2007 Upregulation of aspartoacylase seen in diabetes is due to advanced glycation end-products Med Hypotheses 68 926 17107756
74. S Surendran 2008 N-Acetyl aspartate induces nitric oxide to result neurodegeneration in Canavan disease Biosci hypotheses 1 228 229
75. YJ Song GM Halliday JL Holton T Lashley SS O'Sullivan H McCann AJ Lees T Ozawa DR Williams PJ Lockhart TR Revesz 2009 Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression J Neuropathol Exp Neurol 68 1073 1083 19918119
76. LS Forno LE DeLanney I Irwin D Di Monte JW Langston 1992 Astrocytes and Parkinson's disease Prog Brain Res 94 429 436 1287728
77. SA Khan S Priyamvada N Farooq S Khan MW Khan AN Yusufi 2009 Protective effect of green tea extract on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney Pharmacol Res 59 254 262 19429467
78. Q Guo BL Zhao MF Li SR Shen WJ Xin 1996 Studies on protective mechanisms of four components of green tea polyphenols (GTP) against lipid peroxidation in synaptosomes Biochim Biophys Acta 1304 210 222 8982267
79. Q Guo BL Zhao JW Hou WJ Xin 1999 ESR study on the structure-antioxidant activity relationship of tea catechins and their epimers Biochim Biophys Acta 1427 13 23 10082983
80. BL Zhao Q Guo WJ Xin 2001 Free radical scavenging by green tea polyphenols Methods Enzymol 335 217 231 11400370
81. GJ Nie TT Wei BL Zhao 2001 Polyphenol protection of DNA against damage Methods Enzymol 335 232 244 11400371
82. O Inanami Y Watanabe B Syuto M Nakano M Tsuji M Kuwabara 1998 Oral administration of (-) catechin protects against ischemia-reperfusion-induced neuronal death in the gerbil Free Radic Res 29 359 365 9860051
83. T Yoneda M Hiramatsu N Skamoto K Togasaki M Komatsu K Yamaguchi 1995 Antioxidant effects of ''b catechin'' Biochem Mol Biol Int 35 995 1008 7549942
84. MS Kurzer X Xu 1997 Dietary phytoestrogens Annu Rev Nutr 17 353 381 9240932
85. WH Chan JS Yu 2000 Inhibition of UV irradiation-induced oxidative stress and apoptotic biochemical changes in human epidermal carcinoma A431 cells by genistein J Cell Biochem 78 73 84 10797567
86. KL Johnson F Vaillant A Lawen 1996 Protein tyrosine kinase inhibitors prevent didemnin B-induced apoptosis in HL-60 cells FEBS Lett 383 1 5 8612773
87. JY Choi CS Park DJ Kim MH Cho BK Jin JE Pie WG Chung 2002 Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate Neurotoxicology 23 367 374 12387363
88. JB Schulz RT Matthews MM Muquit SE Browne MF Beal 1995 Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice J Neurochem 64 936 939 7530297
89. P Hantraye E Brouillet R Ferrante S Palfi R Dolan RT Matthews MF Beal 1996 Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons Nat Med 2 1017 1021 8782460
90. A Masci D Mastronicola M Arese M Piane A De Amicis TJ Blanck L Chessa P Sarti 2008 Control of cell respiration by nitric oxide in ataxia telangiectasia lymphoblastoid cells Biochim Biophys Acta 1777 66 73 18047827
91. CW Shults MF Beal D Fontaine K Nakano RH Haas 1998 Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients Neurology 50 793 795 9521279
92. MF Beal RT Matthews A Tieleman CW Shults 1998 Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1, 2, 3, tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice Brain Res 783 109 114 9479058
93. JL Ridet JC Bensadoun N Deglon P Aebischer AD Zurn 2006 Lentivirus-mediated expression of glutathione peroxidase: neuroprotection in murine models of Parkinson's disease Neurobiol Dis 21 29 34 16023352
94. M Thiruchelvam O Prokopenko DA Cory-Slechta EK Richfield B Buckley O Mirochnitchenko 2005 Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat + maneb-induced Parkinson disease phenotype J Biol Chem 280 22530 22539 15824117
95. I Shoulson 1998 DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism Ann Neurol 44 S160 166 9749589
96. S McCarthy M Somayajulu M Sikorska H Borowy-Borowski S Pandey 2004 Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble coenzyme Q10 Toxicol Appl Pharmacol 201 21 31 15519605
97. TL Horvath S Diano C Leranth LM Garcia-Segura MA Cowley M Shanabrough JD Elsworth P Sotonyi RH Roth EH Dietrich RT Matthews CJ Barnstable DE Redmond Jr 2003 Coenzyme Q induces nigral mitochondrial uncoupling and prevents nigral cell loss in a primate model of Parkinson's disease Endocrinology 144 2757 2760 12810526
98. CW Shults D Oakes K Kieburtz MF Beal R Haas S Plumb JL Juncos, et al. 2002 Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline Arch Neurol 59 1541 1550 12374491
99. P Klivenyi D Siwek G Gardian L Yang A Starkov C Cleren RJ Ferrante NW Kowall A Abeliovich MF Beal 2006 Mice lacking alpha-synuclein are resistant to mitochondrial toxins Neurobiol Dis 21 541 548 16298531
100. Parkinson Study Group 2004 A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease Arch Neurol 61 561 566
101. H Chen SM Zhang MA Hernan MA Schwarzschild WC Willett GA Colditz FE Speizer A Ascherio 2003 Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease Arch Neurol 60 1059 1064 12925360
102. M Lagouge C Argmann Z Gerhart-Hines H Meziane C Lerin F Daussin N Messadeq J Milne, et al. 2006 Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α Cell 127 1109 1122 17112576
103. KT Lu MC Ko BY Chen JC Huang CW Hsieh MC Lee RY Chiou BS Wung CH Peng YL Yang 2008 Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging J Agric Food Chem 56 6910 6913 18616261
104. S Fahn D Oakes I Shoulson K Kieburtz A Rudolph A Lang CW Olanow, et al. 2004 Levodopa and the progression of Parkinson's disease N Engl J Med 351 2498 2508 15590952
105. MA Hely WG Reid MA Adena GM Haliday JG Morris 2008 The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years Mov Disord 23 837 844 18307261
106. O Rascol C Goetz W Koller W Poewe C Sampaio 2002 Treatment interventions for Parkinson's disease: an evidence based assessment Lancet 359 1589 1598 12047983
107. D Grosset 2008 Dopamine agonists and therapy compliance Neurol Sci 29 S375 376 19381766